SCHEDULE 13G/A: Camber Capital Management LP and Stephen DuBois Disclose 3.41% Stake in Myriad Genetics Inc.

Camber Capital Management LP and Stephen DuBois have disclosed a shared beneficial ownership of 3.41% in Myriad Genetics Inc., totaling 3,100,000 shares of common stock.

Summary

• Camber Capital Management LP and Stephen DuBois jointly reported beneficial ownership of Myriad Genetics Inc. common stock.
• They collectively own 3,100,000 shares of Myriad Genetics Inc. common stock.
• This ownership represents 3.41% of the company's outstanding common stock.
• The filing is an Amendment No. 3 to a previous Schedule 13G statement.
• Both reporting persons, Camber Capital Management LP (a Delaware limited partnership) and Stephen DuBois (a U.S. citizen), have shared voting and shared dispositive power over these 3,100,000 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor. While it indicates continued investment, it does not provide new operational or financial information to significantly alter sentiment, thus leaning neutral to slightly positive due to the presence of an institutional holder.

Positives

• A notable institutional investor, Camber Capital Management LP, maintains a significant stake in Myriad Genetics Inc., potentially indicating continued investment interest in the company.

Risks

• The filing itself does not detail specific risks related to Myriad Genetics Inc.'s operations or financial health, as it is solely focused on beneficial ownership disclosure.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Myriad Genetics Inc.'s future performance or strategic outlook.

Industry Context

This filing indicates continued investment by Camber Capital Management LP in Myriad Genetics Inc., a company operating within the healthcare and genetics industry, specializing in genetic testing and precision medicine. Such disclosures provide transparency on institutional investor sentiment within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, offering insight into the investor base.
• Company Management: Informs management of the current ownership structure and the continued presence of a significant institutional investor.

Key Dates

Keywords

Myriad Genetics Inc., Camber Capital Management LP, Stephen DuBois, Schedule 13G, beneficial ownership, common stock, institutional investment, healthcare, genetics